Literature DB >> 23639709

Aspirin desensitization in aspirin-exacerbated respiratory disease.

Andrew A White1, Donald D Stevenson.   

Abstract

Although aspirin desensitization was discovered in 1922, it was not until 1979 that a therapeutic use for aspirin treatment, under the protection of desensitization, was discovered. In the last 33 years, details of aspirin treatment have been refined to the point where it is now recognized and accepted as a major therapeutic intervention in the treatment of aspirin-exacerbated respiratory disease, with therapeutic efficacy in approximately two-thirds of patients. It is only effective in patients who have aspirin-exacerbated respiratory disease and none of the other nonsteroidal anti-inflammatory drugs, despite their cross-reactive inhibition of cyclooxygenase-1, can effectively take the place of aspirin.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23639709     DOI: 10.1016/j.iac.2012.10.013

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  6 in total

1.  Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease.

Authors:  Elina Jerschow; Matthew L Edin; Teresa Pelletier; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin Fried; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Weiguo Han; Golda Hudes; Taha Keskin; Victor L Schuster; Simon Spivack; Darryl C Zeldin; David Rosenstreich
Journal:  J Allergy Clin Immunol Pract       Date:  2017-01-31

2.  Biology of nasal polyposis.

Authors:  Whitney W Stevens; Robert P Schleimer; Rakesh K Chandra; Anju T Peters
Journal:  J Allergy Clin Immunol       Date:  2014-05       Impact factor: 10.793

Review 3.  Pathogenesis of nasal polyposis.

Authors:  K E Hulse; W W Stevens; B K Tan; R P Schleimer
Journal:  Clin Exp Allergy       Date:  2015-02       Impact factor: 5.018

4.  Regular Treatment With Aspirin 300 mg/day After Desensitization in Patients With N-ERD: 12-Year Results.

Authors:  Saltuk Buğra Kaya; Mehmet Erdem Çakmak; Ebru Damadoğlu; Gül Karakaya; Ali Fuat Kalyoncu
Journal:  Turk Thorac J       Date:  2021-09

Review 5.  The Nose as a Route for Therapy: Part 1. Pharmacotherapy.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Dimitrios I Mitsias; Nikolaos G Papadopoulos; Ludger Klimek; Anu Laulajainen-Hongisto; Maija Hytönen; Sanna Katriina Toppila-Salmi; Glenis Kathleen Scadding
Journal:  Front Allergy       Date:  2021-02-22

Review 6.  Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients.

Authors:  Rik J L van der Lans; Wytske J Fokkens; Sietze Reitsma
Journal:  Front Allergy       Date:  2021-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.